טוען...
Octreotide Does Not Inhibit Proliferation in Five Neuroendocrine Tumor Cell Lines
Somatostatin analogs (SSA) are well-established antisecretory drugs in functionally active neuroendocrine tumors (NET). Two placebo-controlled trials have recently demonstrated significant improvement of progression-free survival under SSA treatment. Furthermore, somatostatin receptor (SSTR) overexp...
שמור ב:
| הוצא לאור ב: | Front Endocrinol (Lausanne) |
|---|---|
| Main Authors: | , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Frontiers Media S.A.
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5897986/ https://ncbi.nlm.nih.gov/pubmed/29681888 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fendo.2018.00146 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|